rss
Br J Ophthalmol 1999;83:847-851 doi:10.1136/bjo.83.7.847
  • Original Article
    • Laboratory science

Soluble ICAM-1 serum levels in patients with intermediate uveitis

  1. Anne-Marie Kloka,b,c,
  2. Leny Luyendijka,
  3. Michel J W Zaalb,
  4. Aniki Rothovad,
  5. Aize Kijlstraa,c
  1. aDepartment Ophthalmo-Immunology, Netherlands Ophthalmic Research Institute, Amsterdam, bDepartment of Ophthalmology, Free University, Amsterdam, cDepartment of Ophthalmology, University of Amsterdam, Amsterdam, dDepartment of Ophthalmology, University of Utrecht, Utrecht
  1. Anne-Marie Klok, Department Ophthalmo-Immunology, Netherlands Ophthalmic Research Institute, Amsterdam, PO Box 12141, 1100 AC Amsterdam, Netherlands.
  • Accepted 12 January 1999

Abstract

AIM To investigate whether serum levels of soluble intercellular adhesion molecule 1 (sICAM-1) can serve as a marker of the presence of systemic disease in intermediate uveitis.

METHODS In a multicentre study sICAM-1 serum levels were measured in 61 patients with idiopathic intermediate uveitis, controls included 56 uveitis patients with a systemic disease (26 sarcoid associated uveitis and 30 HLA-B27 positive acute anterior uveitis), 58 uveitis patients without systemic disease (30 toxoplasma chorioretinitis and 28 Fuchs’ hetrochromic cyclitis), and 21 normal controls. The clinical records of the patients with intermediate uveitis were analysed for disease characteristics at the time of blood sampling and for a relation with the development of a systemic disease after a mean follow up of 4.5 years.

RESULTS Increased serum levels of sICAM-1 were found in 34 out of 61 patients with intermediate uveitis and were significantly different when compared with toxoplasmosis, Fuchs’ cyclitis, and healthy controls (p<0.001). Elevated sICAM-1 levels were also found in 18 out of 26 patients with sarcoid uveitis and in 11 out of 30 patients with HLA-B27 associated anterior uveitis. Raised sICAM-1 levels in the intermediate uveitis group were significantly associated with active ocular disease (p<0.01) and the presence of vitreous exudates (p<0.05). Increased levels of sICAM-1 correlated with interleukin 8 levels (IL-8) (tested in a previous study in the same group of intermediate uveitis patients) in patients with active systemic involvement. Follow up of the patients showed that an established or suspected systemic disease was found more often in the 21 intermediate uveitis patients with increased sICAM-1 and IL-8 levels compared with the other 40 patients with intermediate uveitis (p<0.01).

CONCLUSIONS The measurement of both sICAM-1 and IL-8 can be used as a marker for ocular disease activity and for a predisposition of developing an associated systemic disease in intermediate uveitis patients.

Footnotes

    This Article

    1. Abstract
    2. Full text
    3. PDF

    Responses

    1. Submit a response
    2. No responses published

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.